Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05309616 · ClinicalTrials.gov registry record · Phase 2
Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis
A Phase 2 study of Idiopathic Subglottic Stenosis, sponsored by Yale University.
- Active
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT05309616 is a Phase 2 study of Idiopathic Subglottic Stenosis that is active but no longer recruiting, run by Yale University. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05309616, a Phase 2 study of Idiopathic Subglottic Stenosis, is active but no longer recruiting, sponsored by Yale University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this phase 2 study is to examine if inhibiting IL-17A activation using the biologic drug Taltz, in idiopathic subglottic stenosis patients will decrease scar fibroblast proliferation therefore reducing or eliminating the need for invasive or repeat surgeries.
Conditions Studied
Interventions
- DRUG Taltz
Study Locations (1)
Connecticut
- Yale New Haven Hospital - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-02-20 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05309616
The ClinicalTrials.gov registry entry for NCT05309616 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Idiopathic Subglottic Stenosis appearing as the primary indexed condition, and to 1 intervention - of which Taltz is the first listed.
NCT05309616 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT05309616 about?
NCT05309616 is a clinical study titled "Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis". The purpose of this phase 2 study is to examine if inhibiting IL-17A activation using the biologic drug Taltz, in idiopathic subglottic stenosis patients will decrease scar fibroblast proliferation therefore reducing or eliminating the need for invasive or repeat surgeries.
What is the current status of trial NCT05309616?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2025-02-20. Estimated completion is 2026-05.
What conditions does trial NCT05309616 study?
This clinical trial studies the following conditions: Idiopathic Subglottic Stenosis.
What interventions are being tested in trial NCT05309616?
The interventions under investigation include: Taltz (DRUG).
Who is sponsoring clinical trial NCT05309616?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05309616 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.